Drug-CDx Sponsors Must Educate Sites to Avoid Approval-Killing Bias

Washington Drug Letter
Sponsors of new drugs seeking approval with a companion in vitro diagnostic (IVD) need to work with trial sites to ensure they are not prescreening patients by local test methods — a process that can prove fatal for regulatory approval, an expert says.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00